Adocia SA, a clinical-stage biotechnology company headquartered in Lyon, France, continues to make strides in the health care sector, particularly within the realm of diabetes and metabolic disease treatment. As a company listed on the NYSE Euronext Paris, Adocia has been a focal point for investors and industry observers alike, especially given its innovative approach to therapeutic protein formulations.
Founded in 2005, Adocia has carved out a niche with its proprietary BioChaperone technological platform. This platform is designed to enhance the efficacy and safety of therapeutic proteins through the use of novel polymers, oligomers, and small molecules. The company’s commitment to advancing diabetes care is evident in its diverse clinical product pipeline, which includes several insulin formulations and combinations aimed at improving patient outcomes.
Among the notable products in Adocia’s pipeline are the BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analogs. These products are designed to offer faster absorption and action, potentially improving glycemic control for patients with diabetes. Additionally, the HinsBet U100, a rapid-acting formulation of human insulin, and the BioChaperone Combo, which combines basal insulin glargine with rapid-acting insulin lispro, highlight the company’s focus on versatile treatment options.
Further expanding its portfolio, Adocia is developing BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide, and BioChaperone Human Glucagon, an aqueous formulation of human glucagon. These products aim to address various aspects of diabetes management, from mealtime insulin needs to emergency glucagon administration.
In addition to diabetes treatments, Adocia is exploring the potential of its BioChaperone platform in other metabolic conditions. The company is developing BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide, which combine insulin glargine with GLP-1 receptor agonists. These combinations are intended to enhance glucose control while potentially offering additional benefits such as weight management. BioChaperone Teduglutide, an aqueous formulation of teduglutide, targets short bowel syndrome, a condition that can lead to severe malabsorption and nutritional deficiencies. Lastly, BioChaperone Glucagon GLP-1, a combination of glucagon and a GLP-1 receptor agonist, is being developed for obesity treatment, showcasing Adocia’s broader focus on metabolic health.
Adocia’s strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. underscores its commitment to expanding its reach and impact in the global market. This partnership is likely to facilitate the development and commercialization of its innovative products, potentially accelerating their availability to patients in need.
As of December 12, 2025, Adocia’s stock price stood at €7.08, reflecting a moderate level of investor interest. Over the past year, the stock has experienced significant volatility, with a high of €12.40 in October 2025 and a low of €2.86 in April 2025. This range indicates the dynamic nature of the biotechnology sector and the varying investor sentiment towards Adocia’s prospects.
With a market capitalization of €136,982,370, Adocia remains a key player in the biotechnology industry, driven by its innovative approach to diabetes and metabolic disease treatment. As the company continues to advance its clinical pipeline and strategic partnerships, it is poised to make significant contributions to the field of health care, offering hope and improved treatment options for patients worldwide.
